药械

订阅

MedSci主页 / 所有栏目 / 药械

礼来的CGRP抑制剂Emgality喜获FDA批准，成为阵发性丛集性头痛的治疗药物

2019-06-05 不详 MedSci原创

CGRP抑制剂Emgality阵发性丛集性头痛首个药物
关注

美国食品和药物管理局批准将礼来的降钙素基因相关肽（CGRP）抑制剂Emgality（galcanezumab-gnlm），用于治疗成人阵发性丛集性头痛。

美国食品和药物管理局批准将礼来的降钙素基因相关肽（CGRP）抑制剂Emgality（galcanezumab-gnlm），用于治疗成人阵发性丛集性头痛。

FDA药物评估和研究中心神经病学产品部副主任Eric Bastings表示："Emgality是FDA第一个批准的药物，可以减少阵发性丛集性头痛的发作频率。"

涉及106名患者的研究结果显示，在三周期间，给予Emgality的患者每周集群头痛发作的次数比基线时少8.7次，而安慰剂组患者的发作次数减少5.2次。

Emgality最初由FDA去年九月批准用于成人偏头痛的预防性治疗。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1852016, encodeId=d81218520164b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 12 10:27:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839694, encodeId=b5ad1839694c5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 13 12:27:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951933, encodeId=c52f19519339b, content=<a href='/topic/show?id=6f6545546c' target=_blank style='color:#2F92EE;'>#CGRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4554, encryptionId=6f6545546c, topicName=CGRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Tue Oct 08 12:27:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936895, encodeId=f0d919368957d, content=<a href='/topic/show?id=129f6e2351' target=_blank style='color:#2F92EE;'>#Emgality#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6723, encryptionId=129f6e2351, topicName=Emgality)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Thu Jul 04 16:27:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921752, encodeId=b35d1921e52bf, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Feb 24 01:27:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055318, encodeId=362e20553184f, content=<a href='/topic/show?id=44369e6246d' target=_blank style='color:#2F92EE;'>#阵发性丛集性头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97624, encryptionId=44369e6246d, topicName=阵发性丛集性头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sun Feb 02 20:27:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458502, encodeId=157214585020f, content=<a href='/topic/show?id=175e20982ac' target=_blank style='color:#2F92EE;'>#丛集性头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20982, encryptionId=175e20982ac, topicName=丛集性头痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd1b6086520, createdName=hjwang81, createdTime=Fri Jun 07 10:27:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573476, encodeId=ab4915e34763c, content=<a href='/topic/show?id=3aaf455863' target=_blank style='color:#2F92EE;'>#CGRP抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4558, encryptionId=3aaf455863, topicName=CGRP抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=672515881410, createdName=zhaozuguo, createdTime=Fri Jun 07 10:27:00 CST 2019, time=2019-06-07, status=1, ipAttribution=)]
    2019-08-12 jklm09

    #抑制剂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1852016, encodeId=d81218520164b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 12 10:27:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839694, encodeId=b5ad1839694c5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 13 12:27:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951933, encodeId=c52f19519339b, content=<a href='/topic/show?id=6f6545546c' target=_blank style='color:#2F92EE;'>#CGRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4554, encryptionId=6f6545546c, topicName=CGRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Tue Oct 08 12:27:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936895, encodeId=f0d919368957d, content=<a href='/topic/show?id=129f6e2351' target=_blank style='color:#2F92EE;'>#Emgality#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6723, encryptionId=129f6e2351, topicName=Emgality)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Thu Jul 04 16:27:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921752, encodeId=b35d1921e52bf, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Feb 24 01:27:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055318, encodeId=362e20553184f, content=<a href='/topic/show?id=44369e6246d' target=_blank style='color:#2F92EE;'>#阵发性丛集性头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97624, encryptionId=44369e6246d, topicName=阵发性丛集性头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sun Feb 02 20:27:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458502, encodeId=157214585020f, content=<a href='/topic/show?id=175e20982ac' target=_blank style='color:#2F92EE;'>#丛集性头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20982, encryptionId=175e20982ac, topicName=丛集性头痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd1b6086520, createdName=hjwang81, createdTime=Fri Jun 07 10:27:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573476, encodeId=ab4915e34763c, content=<a href='/topic/show?id=3aaf455863' target=_blank style='color:#2F92EE;'>#CGRP抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4558, encryptionId=3aaf455863, topicName=CGRP抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=672515881410, createdName=zhaozuguo, createdTime=Fri Jun 07 10:27:00 CST 2019, time=2019-06-07, status=1, ipAttribution=)]
    2019-11-13 智者为医08

    #FDA批准#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1852016, encodeId=d81218520164b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 12 10:27:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839694, encodeId=b5ad1839694c5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 13 12:27:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951933, encodeId=c52f19519339b, content=<a href='/topic/show?id=6f6545546c' target=_blank style='color:#2F92EE;'>#CGRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4554, encryptionId=6f6545546c, topicName=CGRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Tue Oct 08 12:27:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936895, encodeId=f0d919368957d, content=<a href='/topic/show?id=129f6e2351' target=_blank style='color:#2F92EE;'>#Emgality#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6723, encryptionId=129f6e2351, topicName=Emgality)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Thu Jul 04 16:27:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921752, encodeId=b35d1921e52bf, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Feb 24 01:27:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055318, encodeId=362e20553184f, content=<a href='/topic/show?id=44369e6246d' target=_blank style='color:#2F92EE;'>#阵发性丛集性头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97624, encryptionId=44369e6246d, topicName=阵发性丛集性头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sun Feb 02 20:27:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458502, encodeId=157214585020f, content=<a href='/topic/show?id=175e20982ac' target=_blank style='color:#2F92EE;'>#丛集性头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20982, encryptionId=175e20982ac, topicName=丛集性头痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd1b6086520, createdName=hjwang81, createdTime=Fri Jun 07 10:27:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573476, encodeId=ab4915e34763c, content=<a href='/topic/show?id=3aaf455863' target=_blank style='color:#2F92EE;'>#CGRP抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4558, encryptionId=3aaf455863, topicName=CGRP抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=672515881410, createdName=zhaozuguo, createdTime=Fri Jun 07 10:27:00 CST 2019, time=2019-06-07, status=1, ipAttribution=)]
    2019-10-08 gostraight

    #CGRP#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1852016, encodeId=d81218520164b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 12 10:27:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839694, encodeId=b5ad1839694c5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 13 12:27:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951933, encodeId=c52f19519339b, content=<a href='/topic/show?id=6f6545546c' target=_blank style='color:#2F92EE;'>#CGRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4554, encryptionId=6f6545546c, topicName=CGRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Tue Oct 08 12:27:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936895, encodeId=f0d919368957d, content=<a href='/topic/show?id=129f6e2351' target=_blank style='color:#2F92EE;'>#Emgality#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6723, encryptionId=129f6e2351, topicName=Emgality)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Thu Jul 04 16:27:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921752, encodeId=b35d1921e52bf, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Feb 24 01:27:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055318, encodeId=362e20553184f, content=<a href='/topic/show?id=44369e6246d' target=_blank style='color:#2F92EE;'>#阵发性丛集性头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97624, encryptionId=44369e6246d, topicName=阵发性丛集性头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sun Feb 02 20:27:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458502, encodeId=157214585020f, content=<a href='/topic/show?id=175e20982ac' target=_blank style='color:#2F92EE;'>#丛集性头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20982, encryptionId=175e20982ac, topicName=丛集性头痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd1b6086520, createdName=hjwang81, createdTime=Fri Jun 07 10:27:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573476, encodeId=ab4915e34763c, content=<a href='/topic/show?id=3aaf455863' target=_blank style='color:#2F92EE;'>#CGRP抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4558, encryptionId=3aaf455863, topicName=CGRP抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=672515881410, createdName=zhaozuguo, createdTime=Fri Jun 07 10:27:00 CST 2019, time=2019-06-07, status=1, ipAttribution=)]
    2019-07-04 ms7019579240139182

    #Emgality#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1852016, encodeId=d81218520164b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 12 10:27:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839694, encodeId=b5ad1839694c5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 13 12:27:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951933, encodeId=c52f19519339b, content=<a href='/topic/show?id=6f6545546c' target=_blank style='color:#2F92EE;'>#CGRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4554, encryptionId=6f6545546c, topicName=CGRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Tue Oct 08 12:27:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936895, encodeId=f0d919368957d, content=<a href='/topic/show?id=129f6e2351' target=_blank style='color:#2F92EE;'>#Emgality#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6723, encryptionId=129f6e2351, topicName=Emgality)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Thu Jul 04 16:27:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921752, encodeId=b35d1921e52bf, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Feb 24 01:27:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055318, encodeId=362e20553184f, content=<a href='/topic/show?id=44369e6246d' target=_blank style='color:#2F92EE;'>#阵发性丛集性头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97624, encryptionId=44369e6246d, topicName=阵发性丛集性头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sun Feb 02 20:27:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458502, encodeId=157214585020f, content=<a href='/topic/show?id=175e20982ac' target=_blank style='color:#2F92EE;'>#丛集性头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20982, encryptionId=175e20982ac, topicName=丛集性头痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd1b6086520, createdName=hjwang81, createdTime=Fri Jun 07 10:27:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573476, encodeId=ab4915e34763c, content=<a href='/topic/show?id=3aaf455863' target=_blank style='color:#2F92EE;'>#CGRP抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4558, encryptionId=3aaf455863, topicName=CGRP抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=672515881410, createdName=zhaozuguo, createdTime=Fri Jun 07 10:27:00 CST 2019, time=2019-06-07, status=1, ipAttribution=)]
    2020-02-24 周虎

    #治疗药物#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1852016, encodeId=d81218520164b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 12 10:27:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839694, encodeId=b5ad1839694c5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 13 12:27:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951933, encodeId=c52f19519339b, content=<a href='/topic/show?id=6f6545546c' target=_blank style='color:#2F92EE;'>#CGRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4554, encryptionId=6f6545546c, topicName=CGRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Tue Oct 08 12:27:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936895, encodeId=f0d919368957d, content=<a href='/topic/show?id=129f6e2351' target=_blank style='color:#2F92EE;'>#Emgality#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6723, encryptionId=129f6e2351, topicName=Emgality)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Thu Jul 04 16:27:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921752, encodeId=b35d1921e52bf, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Feb 24 01:27:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055318, encodeId=362e20553184f, content=<a href='/topic/show?id=44369e6246d' target=_blank style='color:#2F92EE;'>#阵发性丛集性头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97624, encryptionId=44369e6246d, topicName=阵发性丛集性头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sun Feb 02 20:27:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458502, encodeId=157214585020f, content=<a href='/topic/show?id=175e20982ac' target=_blank style='color:#2F92EE;'>#丛集性头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20982, encryptionId=175e20982ac, topicName=丛集性头痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd1b6086520, createdName=hjwang81, createdTime=Fri Jun 07 10:27:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573476, encodeId=ab4915e34763c, content=<a href='/topic/show?id=3aaf455863' target=_blank style='color:#2F92EE;'>#CGRP抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4558, encryptionId=3aaf455863, topicName=CGRP抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=672515881410, createdName=zhaozuguo, createdTime=Fri Jun 07 10:27:00 CST 2019, time=2019-06-07, status=1, ipAttribution=)]
    2020-02-02 12498f17m66暂无昵称

    #阵发性丛集性头痛#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1852016, encodeId=d81218520164b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 12 10:27:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839694, encodeId=b5ad1839694c5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 13 12:27:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951933, encodeId=c52f19519339b, content=<a href='/topic/show?id=6f6545546c' target=_blank style='color:#2F92EE;'>#CGRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4554, encryptionId=6f6545546c, topicName=CGRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Tue Oct 08 12:27:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936895, encodeId=f0d919368957d, content=<a href='/topic/show?id=129f6e2351' target=_blank style='color:#2F92EE;'>#Emgality#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6723, encryptionId=129f6e2351, topicName=Emgality)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Thu Jul 04 16:27:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921752, encodeId=b35d1921e52bf, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Feb 24 01:27:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055318, encodeId=362e20553184f, content=<a href='/topic/show?id=44369e6246d' target=_blank style='color:#2F92EE;'>#阵发性丛集性头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97624, encryptionId=44369e6246d, topicName=阵发性丛集性头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sun Feb 02 20:27:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458502, encodeId=157214585020f, content=<a href='/topic/show?id=175e20982ac' target=_blank style='color:#2F92EE;'>#丛集性头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20982, encryptionId=175e20982ac, topicName=丛集性头痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd1b6086520, createdName=hjwang81, createdTime=Fri Jun 07 10:27:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573476, encodeId=ab4915e34763c, content=<a href='/topic/show?id=3aaf455863' target=_blank style='color:#2F92EE;'>#CGRP抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4558, encryptionId=3aaf455863, topicName=CGRP抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=672515881410, createdName=zhaozuguo, createdTime=Fri Jun 07 10:27:00 CST 2019, time=2019-06-07, status=1, ipAttribution=)]
    2019-06-07 hjwang81

    #丛集性头痛#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1852016, encodeId=d81218520164b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Aug 12 10:27:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839694, encodeId=b5ad1839694c5, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Nov 13 12:27:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951933, encodeId=c52f19519339b, content=<a href='/topic/show?id=6f6545546c' target=_blank style='color:#2F92EE;'>#CGRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4554, encryptionId=6f6545546c, topicName=CGRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Tue Oct 08 12:27:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936895, encodeId=f0d919368957d, content=<a href='/topic/show?id=129f6e2351' target=_blank style='color:#2F92EE;'>#Emgality#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6723, encryptionId=129f6e2351, topicName=Emgality)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Thu Jul 04 16:27:00 CST 2019, time=2019-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921752, encodeId=b35d1921e52bf, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Mon Feb 24 01:27:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055318, encodeId=362e20553184f, content=<a href='/topic/show?id=44369e6246d' target=_blank style='color:#2F92EE;'>#阵发性丛集性头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97624, encryptionId=44369e6246d, topicName=阵发性丛集性头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Sun Feb 02 20:27:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458502, encodeId=157214585020f, content=<a href='/topic/show?id=175e20982ac' target=_blank style='color:#2F92EE;'>#丛集性头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20982, encryptionId=175e20982ac, topicName=丛集性头痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd1b6086520, createdName=hjwang81, createdTime=Fri Jun 07 10:27:00 CST 2019, time=2019-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573476, encodeId=ab4915e34763c, content=<a href='/topic/show?id=3aaf455863' target=_blank style='color:#2F92EE;'>#CGRP抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4558, encryptionId=3aaf455863, topicName=CGRP抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=672515881410, createdName=zhaozuguo, createdTime=Fri Jun 07 10:27:00 CST 2019, time=2019-06-07, status=1, ipAttribution=)]
    2019-06-07 zhaozuguo

    #CGRP抑制剂#

    0

相关资讯

FDA或将批准CGRP抑制剂eptinezumab以预防偏头痛

Alder Bio生物制药公司近日宣布已提交研究性CGRP抑制剂eptinezumab的申请，以获得FDA的批准用于预防偏头痛。该制药商表示，如果得到FDA的批准，eptinezumab可能会在明年第一季度上市。Alder Bio首席执行官Bob Azelby指出，eptinezumab将成为第一个专门用于快速、有效和持续抑制偏头痛的季度输液疗法。